Long-acting Injectable PrEP: Transforming HIV Strategies
Learn how long-acting injectable PrEP can transform HIV responses in South Africa while bridging treatment access gaps.
Digitisation Drives Netcare's Growth with a 20.7% in HEPS
Discover how digitisation drives Netcare’s growth, reflected in increased revenue and dividends despite economic challenges.
SA Doubles Pledge to Global Fund as Donors Miss Target
South Africa doubles its pledge to the Global Fund replenishment, aiming to combat HIV, TB, and malaria effectively.
Lilly Hits $1 Trillion Valuation with Weight-Loss Success
Eli Lilly hits $1 trillion valuation, marking a historic milestone in the pharmaceutical industry with successful weight-loss drugs.
UK Covid-19 Inquiry Report Highlights Lockdown Failures
The UK Covid-19 Inquiry reveals that 23,000 preventable deaths resulted from lockdown delays and a toxic government culture.
Lenacapavir in Short Supply Amid HIV Epidemic in Africa
Explore the controversy surrounding Lenacapavir in short supply in Africa and the impact on HIV prevention efforts.
China's HIV Prevention Funding Targets Vulnerable Youth
China’s HIV prevention funding of $3.49 million aims to support South Africa’s young people and drug users for better health outcomes.
Public-Private Partnership Slashes Surgical Waiting Lists in KZN
A pioneering public-private healthcare partnership cuts backlogs and addresses inefficiencies in surgery and patient care in KZN.
Life Healthcare Share Price Stumbles Following R2.9bn Liability Adjustment
Life Healthcare share price falls 9% due to R2.9bn adjustment linked to the Piramal liability affecting investor sentiment.
Childhood Hypertension Rates Nearly Double Globally
Delve into the dramatic rise of childhood hypertension and its implications for future health outcomes for young people globally.
Hetero Price Collusion Probe and Its Implications
Uncover the details of the Hetero price collusion probe as the Competition Commission examines key drug procurement allegations.
Ascendis Health Exits JSE and Positions for Growth
Ascendis Health exits JSE following a strong investor mandate as part of its turnaround strategy aimed at unlocking value.